This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Stem Cells. Jan 26, 2014; 6(1): 1-10 Published online Jan 26, 2014. doi: 10.4252/wjsc.v6.i1.1
Dendritic cells derived from pluripotent stem cells: Potential of large scale production
Yan Li, Meimei Liu, Shang-Tian Yang
Yan Li, Department of Chemical and Biomedical Engineering, Florida Agricultural and Mechanical University-Florida State University College of Engineering, Florida State University, Tallahassee, FL 32310, United States
Meimei Liu, Shang-Tian Yang, William G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH 43210, United States
Author contributions: Li Y prepared the original draft; Liu M contributed to writing and editing some sections in the manuscript; and Yang ST revised and finalized the manuscript.
Supported by In part by Florida State University start up fund and Florida State University Research Foundation GAP award; and the partial support from National Science Foundation, No. 1342192
Correspondence to: Shang-Tian Yang, Professor, William G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, 140 West 19th Ave, Columbus, OH 43210, United States. firstname.lastname@example.org
Telephone: +1-614-2926611 Fax: +1-614-2923769
Received: September 29, 2013 Revised: November 11, 2013 Accepted: December 9, 2013 Published online: January 26, 2014
Core tip: Human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs) are promising sources for hematopoietic cells. This review summarizes recent advances in differentiating hESCs and hiPSCs to dendritic cells (DCs), which are unique immune cells in the hematopoietic system and can be loaded with tumor specific antigen and used as vaccine for cancer immunotherapy. While autologous DCs from peripheral blood are limited in number, human PSC (hPSC)-derived DCs provide a novel alternative cell source for clinical application. Different strategies and effects of shear stress on large-scale production of hPSC-derived DCs in bioreactors are also discussed.